Eventide Asset Management - Q1 2023 holdings

$5.45 Billion is the total value of Eventide Asset Management's 149 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 25.0% .

 Value Shares↓ Weighting
ODFL SellOLD DOMINION FREIGHT LINE IN$151,490,769
+19.8%
444,463
-0.3%
2.78%
+11.4%
LOW SellLOWES COS INC$89,602,358
+0.2%
448,079
-0.2%
1.64%
-6.8%
NEP SellNEXTERA ENERGY PARTNERS LP$88,138,712
-13.8%
1,450,843
-0.5%
1.62%
-19.8%
HZNP SellHORIZON THERAPEUTICS PUB L$87,361,222
-22.9%
800,451
-19.6%
1.60%
-28.3%
APTV SellAPTIV PLC$80,760,645
+20.4%
719,856
-0.1%
1.48%
+12.0%
DLO SellDLOCAL LTD$72,296,498
-22.6%
4,457,244
-25.7%
1.33%
-28.0%
RXDX SellPROMETHEUS BIOSCIENCES INC$71,906,546
-36.7%
670,020
-35.1%
1.32%
-41.1%
CRWD SellCROWDSTRIKE HLDGS INCcl a$68,092,902
+6.3%
496,087
-18.4%
1.25%
-1.1%
KRTX SellKARUNA THERAPEUTICS INC$61,739,073
-39.5%
339,898
-34.6%
1.13%
-43.7%
TTD SellTHE TRADE DESK INC$61,175,446
-6.8%
1,004,358
-31.4%
1.12%
-13.4%
DV SellDOUBLEVERIFY HLDGS INC$56,327,466
-20.3%
1,868,241
-42.0%
1.03%
-25.9%
CLDX SellCELLDEX THERAPEUTICS INC NEW$49,571,085
-24.0%
1,377,740
-5.8%
0.91%
-29.3%
ENTG SellENTEGRIS INC$49,426,033
+6.6%
602,683
-14.8%
0.91%
-0.9%
LSCC SellLATTICE SEMICONDUCTOR CORP$48,977,080
+21.7%
512,849
-17.3%
0.90%
+13.4%
MPWR SellMONOLITHIC PWR SYS INC$48,718,059
+17.1%
97,331
-17.3%
0.89%
+9.0%
LNG SellCHENIERE ENERGY INC$47,449,578
-20.1%
301,076
-24.0%
0.87%
-25.6%
DDOG SellDATADOG INC$35,983,557
-3.2%
495,232
-2.1%
0.66%
-10.0%
NVT SellNVENT ELECTRIC PLC$34,459,479
+6.0%
802,503
-5.0%
0.63%
-1.4%
CCI SellCROWN CASTLE INC$31,459,360
-35.1%
235,052
-34.2%
0.58%
-39.6%
STE SellSTERIS PLC$26,112,780
+1.4%
136,516
-2.1%
0.48%
-5.7%
IMVT SellIMMUNOVANT INC$21,558,900
-67.1%
1,390,000
-62.4%
0.40%
-69.4%
BILL SellBILL HOLDINGS INC$21,453,254
-25.8%
264,398
-0.3%
0.39%
-30.9%
NDAQ SellNASDAQ INC$21,244,817
-26.6%
388,601
-17.6%
0.39%
-31.6%
WMB SellWILLIAMS COS INC$21,042,551
-16.2%
704,707
-7.6%
0.39%
-22.0%
BMRN SellBIOMARIN PHARMACEUTICAL INC$15,976,435
-32.9%
164,299
-28.6%
0.29%
-37.5%
PNR SellPENTAIR PLC$15,006,081
-4.8%
271,505
-22.5%
0.28%
-11.6%
IEX SellIDEX CORP$14,128,409
-10.5%
61,154
-11.6%
0.26%
-16.7%
ESI SellELEMENT SOLUTIONS INC$13,392,566
-24.2%
693,556
-28.6%
0.25%
-29.3%
EHC SellENCOMPASS HEALTH CORP$10,277,864
-11.6%
189,979
-2.3%
0.19%
-17.5%
WEC SellWEC ENERGY GROUP INC$8,925,900
-47.2%
94,165
-47.7%
0.16%
-50.8%
ANNX SellANNEXON INC$7,188,913
-61.7%
1,867,250
-48.5%
0.13%
-64.3%
CMS SellCMS ENERGY CORP$6,907,153
-44.2%
112,531
-42.4%
0.13%
-48.0%
ICPT SellINTERCEPT PHARMACEUTICALS IN$6,728,873
-32.0%
501,033
-37.4%
0.12%
-36.9%
EGP SellEASTGROUP PPTYS INC$5,497,717
-26.9%
33,255
-34.5%
0.10%
-31.8%
ADCT SellADC THERAPEUTICS SA$3,268,120
-54.7%
1,675,959
-10.9%
0.06%
-57.7%
ALXO SellALX ONCOLOGY HLDGS INC$3,005,027
-70.4%
664,829
-26.3%
0.06%
-72.5%
SellARTERIS INC$2,211,465
-16.3%
522,805
-14.9%
0.04%
-21.2%
FRLN SellFREELINE THERAPEUTICS HLDGSsponsored ads$2,163,215
-25.9%
4,702,641
-20.6%
0.04%
-31.0%
ZTS SellZOETIS INCcl a$335,377
-83.1%
2,015
-85.1%
0.01%
-84.6%
NVDA SellNVIDIA CORPORATION$100,831
+22.8%
363
-35.4%
0.00%0.0%
XPO SellXPO INC$6,635
-99.8%
208
-99.8%
0.00%
-100.0%
ZI SellZOOMINFO TECHNOLOGIES INC$26,366
-100.0%
1,067
-100.0%
0.00%
-100.0%
NXPI ExitNXP SEMICONDUCTORS N V$0-369
-100.0%
-0.00%
KALV ExitKALVISTA PHARMACEUTICALS INC$0-276,200
-100.0%
-0.04%
ExitNEXTERA ENERGY INCunit 09/01/2025 added$0-75,000
-100.0%
-0.07%
CMPX ExitCOMPASS THERAPEUTICS INC$0-935,091
-100.0%
-0.09%
ARE ExitALEXANDRIA REAL ESTATE EQ IN$0-32,335
-100.0%
-0.09%
DVN ExitDEVON ENERGY CORP NEW$0-107,657
-100.0%
-0.13%
SNV ExitSYNOVUS FINL CORP$0-184,028
-100.0%
-0.14%
EQT ExitEQT CORP$0-206,291
-100.0%
-0.14%
WD ExitWALKER & DUNLOP INC$0-94,535
-100.0%
-0.15%
PRAX ExitPRAXIS PRECISION MEDICINES I$0-3,518,062
-100.0%
-0.16%
BAX ExitBAXTER INTL INC$0-198,600
-100.0%
-0.20%
FRC ExitFIRST REP BK SAN FRANCISCO C$0-132,371
-100.0%
-0.32%
AESC ExitAES CORPunit 02/15/2024$0-171,200
-100.0%
-0.34%
BCYC ExitBICYCLE THERAPEUTICS PLCsponsored ads$0-853,800
-100.0%
-0.50%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings